On 16 October 2017, orphan designation (EU/3/17/1926) was granted by the European Commission to Envigo Pharma Consulting Limited, United Kingdom, for ofranergene obadenovec (also known as VB-111) for the treatment of ovarian cancer.
The sponsorship was transferred to Envigo CRS S.A., Spain, in April 2019.
|Disease / condition||
Treatment of ovarian cancer
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;